Annexon

ANNX

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$0k

Combined value at quarter end

Last quarter

0 bought

1 sold or trimmed

Price at Q1 ’26 end

$5.54

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

1Q1 ’26

0Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Annexon.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

No manager on this site held it in their latest 13F.

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Annexon
		Bought or sold				Filing
24 Sep 2026	Love DouglasPRESIDENT AND CEO	▲ Bought	26,065	$3.83	$100k	Form 4

About the company

Sector: Health care · Pharmaceutical Preparations
Incorporated in: Delaware
Financial year ends: 31 December
Shares outstanding: 39m at 2 May 2022
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

Annexon revenue and net income by year
Year	Revenue	Net income
2025	–	−$207m
2024	–	−$138m
2023	–	−$134m
2022	–	−$142m
2021	–	−$130m
2020	–	−$63.4m
2019	–	−$37.2m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter

Polen Capital Management in Q2 2026